Abstract
Overview
Introduction
Hepatitis is a major health problem in China, which is home to one third of
hepatitis B patients and one quarter of hepatitis C patients globally. HBV
vaccination, together with HBV and HCV screening have helped to reduce
transmission, but continued transmission from mother to child (for HBV) and
transmission via blood transfusions (HCV) means that HBV and HCV are likely to
remain a problem.
Scope
- Analysis of the current dynamics of the Chinese hepatitis market through
primary research data from 176 physicians, supported by key opinion leaders
- Identification of drivers and resistors of the Chinese hepatitis market,
and how the Chinese healthcare system impacts these market-shaping factors
- Examination of key hepatitis drug regimens for hepatitis in China, and
factors affecting prescription trends underlying these regimens
- Assessment of the differences between China and the 7 major markets in
terms of HBV and HCV transmission and diagnosis
Highlights
Datamonitor physician research indicated that HBV incidence is decreasing in
China. In contrast to the seven major markets, where most patients acquire HBV
sexually, perinatal transmission is the dominant HBV transmission route, which
impacts on HBV disease progression and effectiveness of drug therapy.
Chinese physicians believe that HCV incidence may be increasing in China.
Blood transfusion is though to be the dominant HCV transmission route in
China, while in the seven major markets, HCV is mainly acquired through
intravenous drug use.
Chinese physicians do not consider any HBV therapy a gold-standard, although
lamivudine is the most prescribed first-line therapy, while adefovir is the
most prescribed second-line therapy. While treatment choice is more limited
for HCV, the Chinese HCV market is highly fragmented, with treatment differing
significantly between regions.
Reasons to Purchase
- Review the clinical and commercial factors shaping the uptake of hepatitis
products in China, and the opportunities and threats facing the market
- Gain insight into HBV and HCV prevalence, transmission and coinfection in
China
- Evaluate unmet needs in China's hepatitis market and capitalize on these
opportunities to develop commercial strategies to increase market penetration
| 
View Cart
